• Alexander Nast, Stefanie Rosumeck, Adel Sammain, Ricardo Erdmann, Birte Sporbeck, and Berthold Rzany.
• Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany. alexander.nast@charite.de
• J Dtsch Dermatol Ges. 2011 Jun 1; 9 Suppl 2: e64-84.

BackgroundThis methods report summarizes the methodology used to update the German Psoriasis Guidelines.MethodsThe guidelines were developed following the recommendations of the Association of the Scientific Medical Societies in Germany. Medline, Cochrane Library and Embase were searched to generate new evidence. In addition, the results from the literature search from the EU Psoriasis Guidelines were used. The recommendations were discussed during a consensus conference using nominal group technique and were voted on during the Delphi procedure. An extensive internal and external review (open) was performed.ResultsDue to changes in drug licensing efalizumab was excluded from the guidelines and adalimumab and ustekinumab were added. 97 new studies were included to serve as a basis for the recommendations. The level of evidence improved for calcineurin inhibitors from level 4 to level 2/3 and for MTX and systemic retinoids from level 3 to level 2. A lack of evidence still exists for coal tar (level of evidence 4). All other described interventions have a level of evidence of 2 or 1.ConclusionsThe field of psoriasis therapy is in constant transition. A lack of head to head trials makes direct comparisons still a challenging task. Continuous updating will be necessary to respond to the further changes expected in the field of psoriasis.

8 keywords...

hide…